Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies.

Trial Profile

Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Busulfan (Primary) ; Ciclosporin; Etoposide; Mycophenolate mofetil
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 28 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
    • 13 Jan 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top